Proactive - Interviews for investors

Island Pharmaceuticals CEO: ISLA-101 Shows Promise in Dengue Fever Fight, Phase 2a next

Episode Summary

Island Pharmaceuticals CEO Dr. David Foster joined Steve Darling from Proactive to share exciting updates on the company's progress in developing a potential treatment for dengue fever. Foster revealed that Island Pharmaceuticals continues to achieve promising results from testing its ISLA-101 drug candidate, specifically highlighting highly encouraging pharmacokinetics (PK) data obtained from a single ascending dose study. The latest assessment, conducted on 24 subjects, has provided critical PK data essential for understanding how ISLA-101 interacts within the body. This data is instrumental in establishing appropriate dosing regimens for Island’s planned Phase 2a clinical trial. Notably, the data indicates that even following a single dose, ISLA-101 achieves blood concentrations that have previously been demonstrated to be effective against dengue fever infections. In discussing the significance of these findings, Foster emphasized the urgent need for treatment options for dengue fever, a disease that affects approximately 400 million people annually and is endemic in around 100 countries. Highlighting the severity of the situation, Foster noted that since the beginning of 2024, over two million dengue fever cases and over 500 related deaths have been reported globally. The economic burden of dengue fever is also substantial, with an estimated worldwide annual cost of approximately $13.8 billion. Island Pharmaceuticals' progress in developing ISLA-101 represents a significant step forward in addressing this critical unmet medical need. As the company advances toward its Phase 2a clinical trial, there is optimism for the potential of ISLA-101 to offer an effective treatment option for dengue fever, potentially alleviating the significant burden of this disease on global health and economies. Stay tuned for further updates as Island Pharmaceuticals continues its important work in combating dengue fever. #proactiveinvestors #islandpharmaceuticals #asx #ila #isla-101 #denguefever #GraphiteProduction, #BatteryMaterials, #MauritiusFacility, #MiningInnovation, #SustainableGraphite, #LithiumIonBatteries, #BatteryTechnology, #MiningIndustry, #ModularMining, #MadagascarMine, #EnergyStorage, #GreenEnergy, #EVComponents, #ElectricVehicles, #StrategicPartnerships, #TechAdvancements, #GraphiteSupplyChain, #MineralProcessing, #IndustrialMining, #RenewableResources, #CleanTech, #GraphiteMarket, #FutureOfMining, #InvestInMining#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews